Head-to-head dispatch
Direct Meds vs Nolu
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A rare compounded desk offering both sublingual drops and injectable on either molecule, at all-inclusive no-membership pricing.
Marked down on: FDA issued directmeds.com, Inc. dba DirectMeds a warning letter in September 2025; the letter is public in FDA's warning-letter database
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Desk Score
An all-in, LegitScript-verified GLP-1 line billed every 4 weeks rather than by the calendar month, with no named prescriber or pharmacy behind the price.
Marked down on: Billed "per 4 weeks," not per calendar month — the real annualized cost runs roughly 8% above the $249/$339 headline
Direct Meds takes this head-to-head with the higher Desk Score, 82/100 (B−) against 78/100 (C+) for Nolu. Nolu still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Direct Meds
82/100
B−
Nolu
78/100
C+
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Direct Meds | Nolu |
|---|---|---|
| Semaglutide | $249/mo sublingual · $297/mo injectable | $249/mo injectable · $279/mo oral (billed per 4 weeks) |
| Tirzepatide | $299/mo sublingual · $399/mo injectable | $339/mo injectable (billed per 4 weeks) |
| Coverage | Not publicly listed | All 50 states + DC |
| Brand-name | Compounded only | Compounded only |
| Oral option | Yes | Yes |
| Best for | Patients who want a needle-free sublingual option, or the choice between drops and injection, without a membership fee. | Patients who want one bundled per-order price and will budget for 13 billing cycles a year rather than 12. |
| Desk Score | 82/100B− | 78/100C+ |
The verdict
Desk pick — Direct MedsDirect Meds takes this head-to-head with the higher Desk Score, 82/100 (B−) against 78/100 (C+) for Nolu. Nolu still holds its ground where its strengths line up with yours.
Choose Direct Meds if…
Patients who want a needle-free sublingual option, or the choice between drops and injection, without a membership fee.
$249/mo sublingual · $297/mo injectable sema · $299/mo sublingual · $399/mo injectable tirz · Not publicly listed
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Choose Nolu if…
Patients who want one bundled per-order price and will budget for 13 billing cycles a year rather than 12.
$249/mo injectable · $279/mo oral (billed per 4 weeks) sema · $339/mo injectable (billed per 4 weeks) tirz · All 50 states + DC
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Direct Meds · Nolu.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Direct Meds vs CoreAge Rx
- Nolu vs Vaylen
- Direct Meds vs Strut Health
- Nolu vs Ondra Health
- Direct Meds vs Invigor Medical
- Nolu vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.